BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28951517)

  • 1. Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space.
    Wood O; Clarke J; Woo J; Mirza AH; Woelk CH; Thomas GJ; Vijayanand P; King E; Ottensmeier CH
    Clin Cancer Res; 2017 Dec; 23(24):7641-7649. PubMed ID: 28951517
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma.
    Tawk B; Schwager C; Deffaa O; Dyckhoff G; Warta R; Linge A; Krause M; Weichert W; Baumann M; Herold-Mende C; Debus J; Abdollahi A
    Radiother Oncol; 2016 Feb; 118(2):350-8. PubMed ID: 26711490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.
    Sepiashvili L; Hui A; Ignatchenko V; Shi W; Su S; Xu W; Huang SH; O'Sullivan B; Waldron J; Irish JC; Perez-Ordonez B; Liu FF; Kislinger T
    Mol Cell Proteomics; 2012 Nov; 11(11):1404-15. PubMed ID: 22918226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.
    Muhammad N; Bhattacharya S; Steele R; Phillips N; Ray RB
    Clin Cancer Res; 2017 Jun; 23(12):3120-3128. PubMed ID: 27965308
    [No Abstract]   [Full Text] [Related]  

  • 8. Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs.
    Koshizuka K; Nohata N; Hanazawa T; Kikkawa N; Arai T; Okato A; Fukumoto I; Katada K; Okamoto Y; Seki N
    Oncotarget; 2017 May; 8(18):30288-30304. PubMed ID: 28415821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput sequencing of small RNA transcriptomes reveals critical biological features targeted by microRNAs in cell models used for squamous cell cancer research.
    Severino P; Oliveira LS; Torres N; Andreghetto FM; Klingbeil Mde F; Moyses R; Wünsch-Filho V; Nunes FD; Mathor MB; Paschoal AR; Durham AM
    BMC Genomics; 2013 Oct; 14():735. PubMed ID: 24160351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The non-coding landscape of head and neck squamous cell carcinoma.
    Zou AE; Zheng H; Saad MA; Rahimy M; Ku J; Kuo SZ; Honda TK; Wang-Rodriguez J; Xuan Y; Korrapati A; Yu V; Singh P; Grandis JR; King CC; Lippman SM; Wang XQ; Hinton A; Ongkeko WM
    Oncotarget; 2016 Aug; 7(32):51211-51222. PubMed ID: 27323410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.
    Ginos MA; Page GP; Michalowicz BS; Patel KJ; Volker SE; Pambuccian SE; Ondrey FG; Adams GL; Gaffney PM
    Cancer Res; 2004 Jan; 64(1):55-63. PubMed ID: 14729608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.
    Citron F; Armenia J; Franchin G; Polesel J; Talamini R; D'Andrea S; Sulfaro S; Croce CM; Klement W; Otasek D; Pastrello C; Tokar T; Jurisica I; French D; Bomben R; Vaccher E; Serraino D; Belletti B; Vecchione A; Barzan L; Baldassarre G
    Clin Cancer Res; 2017 Jul; 23(14):3769-3780. PubMed ID: 28174235
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
    Wood O; Woo J; Seumois G; Savelyeva N; McCann KJ; Singh D; Jones T; Peel L; Breen MS; Ward M; Garrido Martin E; Sanchez-Elsner T; Thomas G; Vijayanand P; Woelk CH; King E; Ottensmeier C;
    Oncotarget; 2016 Aug; 7(35):56781-56797. PubMed ID: 27462861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome sequencing uncovers novel long noncoding and small nucleolar RNAs dysregulated in head and neck squamous cell carcinoma.
    Zou AE; Ku J; Honda TK; Yu V; Kuo SZ; Zheng H; Xuan Y; Saad MA; Hinton A; Brumund KT; Lin JH; Wang-Rodriguez J; Ongkeko WM
    RNA; 2015 Jun; 21(6):1122-34. PubMed ID: 25904139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
    Zhang F; Liu Y; Yang Y; Yang K
    BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
    Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
    Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
    Koshizuka K; Hanazawa T; Kikkawa N; Katada K; Okato A; Arai T; Idichi T; Osako Y; Okamoto Y; Seki N
    Auris Nasus Larynx; 2018 Aug; 45(4):854-865. PubMed ID: 29233721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.